Novartis U.K. Site Closure Plan Shakes British R&D Community Anew
This article was originally published in The Pink Sheet Daily
British R&D has taken another knock with news Novartis is closing its respiratory center in the county of West Sussex, England as part of the Swiss group’s wider R&D realignment worldwide. The planned move would mean the loss of up to 371 positions at the Horsham center.
You may also be interested in...
Prime Minister Cameron Plans To Boost U.K. Biotech With New "Catalyst" Fund, Early Patient Access Scheme
The U.K. plans to boost its life sciences sector with a series of measures, including a fund to support early-stage research and allowing early access to innovative medicines before regulatory approval.
ImCheck’s $53m series B financing will be used to develop antibodies that activate gamma delta T-cells for use against cancer and autoimmune diseases, its CEO tells Scrip.
Novartis’s AI head tells Scrip an open-ended collaboration with Amazon Web Services will ‘transform’ the Swiss major’s global manufacturing operations and distribution centers.